Outcomes of Dual Antiplatelet Therapy Beyond One Year in Patients Post-Drug Eluting Stent Placement: A Cohort Study"
DOI:
https://doi.org/10.62497//irjcs.94Keywords:
Platelet Aggregation Inhibitors, Drug-Eluting Stents, Dual Antiplatelet Therapy, Myocardial Infarction, Hemorrhage, Chronic Kidney Disease, Cardiovascular Diseases, Cohort Studies, Risk Factors, Treatment OutcomeAbstract
Introduction: The study aimed to evaluate the outcomes of dual antiplatelet therapy (DAPT) beyond one year in patients who had undergone drug-eluting stent (DES) placement, focusing on major adverse cardiovascular events (MACE), bleeding complications, and the impact of baseline characteristics on these outcomes.
Methodology: This cohort study was conducted at Pakistan Institute of Medical Sciences (PIMS), Islamabad, over a 12-month period. A total of 110 patients who underwent DES placement and continued DAPT for more than one year were included. Data were collected on demographics, comorbidities, antiplatelet regimens, and cardiovascular events. Statistical analyses, including descriptive statistics, chi-square tests, and logistic regression, were performed to assess the outcomes.
Results: The study found that the overall incidence of MACE was 16.4%, with myocardial infarction and target lesion revascularization being the most common complications. Bleeding complications occurred in 16.3% of patients, with 4.5% experiencing major bleeding and 11.8% minor bleeding. Chronic kidney disease (CKD) was identified as a potential risk factor for MACE, although this association was not statistically significant. The antiplatelet regimen (aspirin + clopidogrel vs. aspirin + ticagrelor) did not show a significant difference in outcomes.
Conclusion: Prolonged DAPT beyond one year following DES placement effectively reduces MACE while maintaining a manageable bleeding risk. CKD may be a potential risk factor for adverse outcomes, but further studies with larger sample sizes and longer follow-up are needed to confirm these findings.
Downloads
References
Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G, Gilard M, Feres F, Costa RA, Morice MC, Georges JL. Duration of dual antiplatelet therapy in patients with CKD and drug-eluting stents: a meta-analysis. Clinical Journal of the American Society of Nephrology. 2019 Jun 1;14(6):810-22.
Lee T, D'Souza K, Hameed A, Yao J, Lam S, Chadban S, Ying T, Celermajer D, Sandroussi C, Pleass HC, Laurence JM. Comparison of the effect of single vs dual antiplatelet agents on post-operative haemorrhage after renal transplantation: A systematic review and meta-analysis. Transplantation Reviews. 2021 Jan 1;35(1):100594.
Laehn SJ, Feih JT, Saltzberg MT, Rinka JR. Pharmacodynamic-guided cangrelor bridge therapy for orthotopic heart transplant. Journal of Cardiothoracic and Vascular Anesthesia. 2019 Apr 1;33(4):1054-8.
Swan D, Loughran N, Makris M, Thachil J. Management of bleeding and procedures in patients on antiplatelet therapy. Blood Reviews. 2020 Jan 1;39:100619.
Schneider PA, Laird JR, Doros G, Gao Q, Ansel G, Brodmann M, Micari A, Shishehbor MH, Tepe G, Zeller T. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. Journal of the American College of Cardiology. 2019 May 28;73(20):2550-63.
Ellis SG, Cho L, Raymond R, Nair R, Simpfendorfer C, Tuzcu M, Bajzer C, Lincoff AM, Kapadia S. Comparison of long-term clinical outcomes after drug-eluting stenting in blacks-vs-whites. The American Journal of Cardiology. 2019 Oct 15;124(8):1179-85.
McKittrick CM, Cardona MJ, Black RA, McCormick C. Development of a bioactive polymeric drug eluting coronary stent coating using electrospraying. Annals of biomedical engineering. 2020 Jan;48(1):271-81.
Yasseen YA, Rajeeb AN, Ahmed MH. Acute Inflammatory Response after Novolimus Eluting Bioresorbable Scaffold and Novolimus Eluting Stent Implantation in Al-Najaf Cardiac Center Patients: A Comparative Study. Prensa Med Argent. 2020;106:6.
Tepe G, Brodmann M, Werner M, Bachinsky W, Holden A, Zeller T, Mangalmurti S, Nolte-Ernsting C, Bertolet B, Scheinert D, Gray WA. Intravascular lithotripsy for peripheral artery calcification: 30-day outcomes from the randomized disrupt PAD III trial. Cardiovascular Interventions. 2021 Jun 28;14(12):1352-61.
Rathod J, Sheorain V, Jaybhay S, Shaikh R, Bangde P. Below Knee Angioplasty Using Drug-Eluting Balloons in Patients with Critical Limb Ischemia with Six Months Follow-Up: Single-Center Experience at Tertiary Care Hospital. Journal of Clinical Interventional Radiology ISVIR. 2022 Dec;6(03):177-83.
Yang Y, Chen S, Yan Z, Jiao Y. Clinical advantage of drug-coated balloon in treatment of restenosis in superficial femoral artery stents. American Journal of Translational Research. 2023 Feb 15;15(2):1494.
Ninomiya K, Serruys PW, Colombo A, Reimers B, Basavarajaiah S, Sharif F, Testa L, Di Mario C, Nerla R, Ding D, Huang J. A prospective randomized trial comparing sirolimus-coated balloon with paclitaxel-coated balloon in de novo small vessels. Cardiovascular Interventions. 2023 Dec 11;16(23):2884-96.
Blaško P, Samoš M, Bolek T, Stančiaková L, Škorňová I, Péč MJ, Jurica J, Staško J, Mokáň M. Resistance on the latest oral and intravenous P2Y12 ADP receptor blockers in patients with acute coronary syndromes: fact or myth?. Journal of Clinical Medicine. 2022 Dec 4;11(23):7211.
Cole J, Htun N, Lew R, Freilich M, Quinn S, Layland J. COlchicine to prevent PeriprocEdural myocardial injury in percutaneous coronary intervention (COPE-PCI): a descriptive cytokine pilot sub-study. Cardiovascular Revascularization Medicine. 2022 Jun 1;39:84-9.
Friedman PN, Shaazuddin M, Gong L, Grossman RL, Harralson AF, Klein TE, Lee NH, Miller DC, Nutescu EA, O'Brien TJ, O'Donnell PH. The acco u nt consortium: A model for the discovery, translation, and implementation of precision medicine in african americans. Clinical and translational science. 2019 May;12(3):209-17.
Perla HT, Thomson VS, Attumalil TV, Geevar T, Alex AG, Dave RG, Nair SC, Gowri SM, Mony PK, George P, Joseph G. Randomized, Double-blind, active comparator pharmacodynamic study of platelet inhibition with crushed and integral formulations of clopidogrel and ticagrelor in acute coronary syndrome. American Journal of Cardiovascular Drugs. 2023 Jul;23(4):455-66.
Parker W. Interactions between aspirin and P2Y12 receptor antagonists in ischaemic heart disease (Doctoral dissertation, University of Sheffield).
Sharma YP, Prasad K, Kaur N, Pruthvi CR, Chaudhray A, Panda P. Successful Management of Acute Coronary Syndrome with Cardiogenic Shock, Severe Mitral Regurgitation and Multi-organ Dysfunction: A Case Report. Asian Journal of Cardiology Research. 2021; 4(1): 89-95.
Published
Issue
Section
License
Copyright (c) 2025 Malik Muhammad Usama Khan, Syeda Hafsa Habib, Mahnoor Safeer, Syeda Hajra Habib, Muhammad Zarghama Khan (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
